Vetoquinol's new three-monthly feline parasiticide receives marketing authorisation from the VMD

Vetoquinol UK has been granted marketing authorisation by the VMD for Felpreva – a new endectocide solution that covers all major types of feline parasites in the UK, in a three-monthly spot-on. The announcement follows the granting of authorisation from the European Medicines Agency (EMA).
 
Felpreva will be the first parasiticide for cats to offer 3 months’ flea and tick protection plus treatment against roundworm, tapeworm and ear mites, all in a single spot-on. It also treats lungworm and mange mites and is licensed for the treatment of cats with, or at risk from, mixed parasitic infestations.
 
Felpreva is a unique combination of active substances, emodepside and praziquantel, with tigolaner, a novel active ingredient. For cats with outdoor access, the European Scientific Counsel Companion Animal Parasites (ESCCAP) recommends sampling or worming no less than four times per year, with certain high risk groups requiring more frequent treatments.[1]  As Felpreva is applied four times per year to provide ongoing flea and tick protection, it is also a convenient way to help ensure cats are in compliance with this minimum recommendation for worming.
 
Helen Hunter, Senior Product Manager – Companion Animal at Vetoquinol, said: “The need for an endectocide solution like Felpreva has never been greater. Issues like the pandemic pet ownership boom have meant that veterinary professionals are looking after more pets than ever. This marketing authorisation will allow us to bring convenience, longer-lasting protection, and ease of use to veterinary professionals and owners alike, in turn safeguarding the wellbeing of our feline companions.”
 
It is anticipated that Felpreva will be made available to vets across the UK in early 2022.
  
 
 
[1] ESCCAP, guideline 01: ‘Worm Control in Dogs and Cats’